From the Division of Public Mental Health and Population Sciences, Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, CA (JD, MY, FR, HCG, MMG); Division of Primary Care and Population Health, Department of Medicine, Stanford University School of Medicine, Stanford, CA (CBJ, MMG); and Integrated Substance Abuse Programs, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA (HB, VPA, SL, RR).
J Addict Med. 2023;17(1):60-66. doi: 10.1097/ADM.0000000000001035. Epub 2022 Jul 15.
INTRODUCTION: The opioid epidemic has evolved into a combined stimulant epidemic, with escalating stimulant and fentanyl-related overdose deaths. Primary care providers are on the frontlines grappling with patients' methamphetamine use. Although effective models exist for treating opioid use disorder in primary care, little is known about current clinical practices for methamphetamine use. METHODS: Six semistructured group interviews were conducted with 38 primary care providers. Interviews focused on provider perceptions of patients with methamphetamine use problems and their care. Data were analyzed using inductive and thematic analysis and summarized along the following dimensions: (1) problem identification, (2) clinical management, (3) barriers and facilitators to care, and (4) perceived needs to improve services. RESULTS: Primary care providers varied in their approach to identifying and treating patient methamphetamine use. Unlike opioid use disorders, providers reported lacking standardized screening measures and evidence-based treatments, particularly medications, to address methamphetamine use. They seek more standardized screening tools, Food and Drug Administration-approved medications, reliable connections to addiction medicine specialists, and more training. Interest in novel behavioral health interventions suitable for primary care settings was also noteworthy. CONCLUSIONS: The findings from this qualitative analysis revealed that primary care providers are using a wide range of tools to screen and treat methamphetamine use, but with little perceived effectiveness. Primary care faces multiple challenges in effectively addressing methamphetamine use among patients singularly or comorbid with opioid use disorders, including the lack of Food and Drug Administration-approved medications, limited patient retention, referral opportunities, funding, and training for methamphetamine use. Focusing on patients' medical issues using a harm reduction, motivational interviewing approach, and linkage with addiction medicine specialists may be the most reasonable options to support primary care in compassionately and effectively managing patients who use methamphetamines.
简介:阿片类药物泛滥已经演变成一种混合兴奋剂泛滥,兴奋剂和芬太尼相关的过量死亡人数不断上升。初级保健提供者处于应对患者甲基苯丙胺使用问题的前沿。虽然在初级保健中治疗阿片类药物使用障碍有有效的模式,但对于甲基苯丙胺使用的当前临床实践知之甚少。 方法:对 38 名初级保健提供者进行了 6 次半结构化小组访谈。访谈重点是提供者对有甲基苯丙胺使用问题的患者的看法及其护理。使用归纳和主题分析对数据进行分析,并沿以下维度进行总结:(1)问题识别,(2)临床管理,(3)护理的障碍和促进因素,以及(4)改善服务的感知需求。 结果:初级保健提供者在识别和治疗患者甲基苯丙胺使用问题的方法上存在差异。与阿片类药物使用障碍不同,提供者报告缺乏标准化的筛查措施和循证治疗方法,特别是药物,来解决甲基苯丙胺的使用问题。他们寻求更标准化的筛查工具、食品和药物管理局批准的药物、可靠的成瘾医学专家联系以及更多的培训。对适合初级保健环境的新型行为健康干预措施的兴趣也值得注意。 结论:这项定性分析的结果表明,初级保健提供者正在使用广泛的工具来筛查和治疗甲基苯丙胺的使用,但效果不佳。初级保健在有效解决单独或并发阿片类药物使用障碍的患者的甲基苯丙胺使用问题上面临多种挑战,包括缺乏食品和药物管理局批准的药物、有限的患者保留率、转介机会、资金和甲基苯丙胺使用培训。使用减少伤害、动机访谈方法并与成瘾医学专家联系关注患者的医疗问题,可能是支持初级保健以富有同情心和有效地管理使用甲基苯丙胺的患者的最合理选择。
J Subst Use Addict Treat. 2023-8
Harm Reduct J. 2022-5-25
Addict Sci Clin Pract. 2021-10-11
J Psychoactive Drugs. 2024-9-2
Front Toxicol. 2023-3-8
Curr Opin Psychiatry. 2021-7-1
Addict Behav. 2021-1
PLoS One. 2020-6-18
Hum Psychopharmacol. 2019-9